Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci

Aimee K. Zaas, Xiaoyan Song, Pamela Tucker, Trish M. Perl

Research output: Contribution to journalArticle

Abstract

Vancomycin-resistant Enterococcus faecium (VRE) is a common nosocomial isolate, especially among patients with cancer. VRE infections have substantial attributable mortality among patients with cancer. The purpose of this study was to identify risk factors for developing bloodstream infection with VRE in patients with cancer who are colonized with VRE. VRE colonization was prospectively identified in 197 patients with cancer during 4-year period, of whom 179 (91%) had complete records for evaluation. Of these 179 patients, 24 (13.4%) developed hospital-acquired VRE bloodstream infections. Risk factors for VRE bloodstream infection included vancomycin use (relative risk [RR], 1.98; 95% confidence interval [CI], 1.25-3.14), diabetes mellitus (RR, 3.91; 95% CI, 1.20-12.77), gastrointestinal procedures (RR, 4.56; 95% CI, 1.05-19.7), and acute renal failure (RR, 3.10; 95% CI, 1.07-8.93). Strategies for preventing VRE bloodstream infection in VRE-colonized patients with cancer should include limiting vancomycin use and, perhaps, gastrointestinal procedures.

Original languageEnglish (US)
Pages (from-to)1139-1146
Number of pages8
JournalClinical Infectious Diseases
Volume35
Issue number10
DOIs
StatePublished - Nov 15 2002

Fingerprint

Enterococcus faecium
Vancomycin
Infection
Neoplasms
Confidence Intervals
Vancomycin-Resistant Enterococci
Acute Kidney Injury
Diabetes Mellitus
Mortality

ASJC Scopus subject areas

  • Immunology

Cite this

Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. / Zaas, Aimee K.; Song, Xiaoyan; Tucker, Pamela; Perl, Trish M.

In: Clinical Infectious Diseases, Vol. 35, No. 10, 15.11.2002, p. 1139-1146.

Research output: Contribution to journalArticle

@article{8be961df8e1046b3bb4e16b6b6d48541,
title = "Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci",
abstract = "Vancomycin-resistant Enterococcus faecium (VRE) is a common nosocomial isolate, especially among patients with cancer. VRE infections have substantial attributable mortality among patients with cancer. The purpose of this study was to identify risk factors for developing bloodstream infection with VRE in patients with cancer who are colonized with VRE. VRE colonization was prospectively identified in 197 patients with cancer during 4-year period, of whom 179 (91{\%}) had complete records for evaluation. Of these 179 patients, 24 (13.4{\%}) developed hospital-acquired VRE bloodstream infections. Risk factors for VRE bloodstream infection included vancomycin use (relative risk [RR], 1.98; 95{\%} confidence interval [CI], 1.25-3.14), diabetes mellitus (RR, 3.91; 95{\%} CI, 1.20-12.77), gastrointestinal procedures (RR, 4.56; 95{\%} CI, 1.05-19.7), and acute renal failure (RR, 3.10; 95{\%} CI, 1.07-8.93). Strategies for preventing VRE bloodstream infection in VRE-colonized patients with cancer should include limiting vancomycin use and, perhaps, gastrointestinal procedures.",
author = "Zaas, {Aimee K.} and Xiaoyan Song and Pamela Tucker and Perl, {Trish M.}",
year = "2002",
month = "11",
day = "15",
doi = "10.1086/342904",
language = "English (US)",
volume = "35",
pages = "1139--1146",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci

AU - Zaas, Aimee K.

AU - Song, Xiaoyan

AU - Tucker, Pamela

AU - Perl, Trish M.

PY - 2002/11/15

Y1 - 2002/11/15

N2 - Vancomycin-resistant Enterococcus faecium (VRE) is a common nosocomial isolate, especially among patients with cancer. VRE infections have substantial attributable mortality among patients with cancer. The purpose of this study was to identify risk factors for developing bloodstream infection with VRE in patients with cancer who are colonized with VRE. VRE colonization was prospectively identified in 197 patients with cancer during 4-year period, of whom 179 (91%) had complete records for evaluation. Of these 179 patients, 24 (13.4%) developed hospital-acquired VRE bloodstream infections. Risk factors for VRE bloodstream infection included vancomycin use (relative risk [RR], 1.98; 95% confidence interval [CI], 1.25-3.14), diabetes mellitus (RR, 3.91; 95% CI, 1.20-12.77), gastrointestinal procedures (RR, 4.56; 95% CI, 1.05-19.7), and acute renal failure (RR, 3.10; 95% CI, 1.07-8.93). Strategies for preventing VRE bloodstream infection in VRE-colonized patients with cancer should include limiting vancomycin use and, perhaps, gastrointestinal procedures.

AB - Vancomycin-resistant Enterococcus faecium (VRE) is a common nosocomial isolate, especially among patients with cancer. VRE infections have substantial attributable mortality among patients with cancer. The purpose of this study was to identify risk factors for developing bloodstream infection with VRE in patients with cancer who are colonized with VRE. VRE colonization was prospectively identified in 197 patients with cancer during 4-year period, of whom 179 (91%) had complete records for evaluation. Of these 179 patients, 24 (13.4%) developed hospital-acquired VRE bloodstream infections. Risk factors for VRE bloodstream infection included vancomycin use (relative risk [RR], 1.98; 95% confidence interval [CI], 1.25-3.14), diabetes mellitus (RR, 3.91; 95% CI, 1.20-12.77), gastrointestinal procedures (RR, 4.56; 95% CI, 1.05-19.7), and acute renal failure (RR, 3.10; 95% CI, 1.07-8.93). Strategies for preventing VRE bloodstream infection in VRE-colonized patients with cancer should include limiting vancomycin use and, perhaps, gastrointestinal procedures.

UR - http://www.scopus.com/inward/record.url?scp=0037111760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037111760&partnerID=8YFLogxK

U2 - 10.1086/342904

DO - 10.1086/342904

M3 - Article

C2 - 12410472

AN - SCOPUS:0037111760

VL - 35

SP - 1139

EP - 1146

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

ER -